The Blood-Pressure Pill That Fakes Starvation (If You’re a Worm)
A drug already sitting in medicine cabinets for high blood pressure made lab worms live longer, and it did that without a single missed meal. In a 2023 study published in Aging Cell, researchers from the University of Liverpool, ETH Zürich, and Harvard Medical School, including Dominic F. Bennett, Anita Goyala, Cyril Statzer, Charles W. Beckett, Alexander Tyshkovskiy, Vadim N. Gladyshev, Collin Y. Ewald, and João Pedro de Magalhães, went looking for existing compounds that switch on the same gene-activity signature as caloric restriction. They found one: rilmenidine, an I1-imidazoline receptor agonist prescribed for hypertension. Dosed onto Caenorhabditis elegans, a soil-dwelling roundworm about 0.04 inches (1 millimeter) long, using the standard laboratory strain N2, the drug extended lifespan in both young and older worms. No fasting. No reduced rations. Just the pill.
The Switch Called nish-1
The effect traces back to one receptor. In these worms, rilmenidine worked through a specific receptor variant called nish-1. The team ran the test that separates a real mechanism from a coincidence: they deleted the gene for nish-1 in a separate batch of worms, then dosed them with rilmenidine. The lifespan boost vanished. Restore the receptor, and the extended lifespan came right back.
Downstream of nish-1, treated worms needed two transcription factors, FOXO/DAF-16 and NRF1,2,3/SKN-1, to get the benefit, and they leaned hard on autophagy, the cell’s system for breaking down and clearing out damaged proteins. Blocking AMPK signaling, a pathway usually associated with energy stress, did not stop the effect. Worms on rilmenidine also tolerated heat stress better than untreated worms, while their development and fertility did not shift at all. That last detail matters: the drug was not slowing the worms down in some general way. It hit an aging pathway specifically, and it hit a ceiling too. When the researchers combined rilmenidine with actual caloric restriction, or with rapamycin, or with a genetic dial-down of the TORC1 growth pathway, the worms got no extra lifespan on top of what rilmenidine alone provided. That is the signature of a pill and a diet flipping the same switch, not two different ones.
One Receptor, Two Species
The same paper checked whether this was a nematode-only trick, and it was not. In mice, rilmenidine treatment switched on gene activity in liver and kidney tissue that matched the pattern normally produced by real caloric restriction. Genes known to shift in unusually long-lived mice moved in that same direction after rilmenidine, with no change to what the mice ate. A cellular response evolution built to react to actual food scarcity can, it turns out, be switched on chemically, in a microscopic worm and in a mammal, by the same compound.
The Myth This Kills
Strict, sustained caloric restriction has long looked like the only door into these longevity-linked cellular switches. Restriction studies have tied cutting food intake to exactly this kind of benefit, and human trials of restriction have run into low compliance and real downsides. Here, in C. elegans, the same molecular switch flipped from a pill instead. The myth is not that caloric restriction doesn’t work. It is the idea that restriction is the only key that fits the lock.
There’s a second myth worth naming directly, because it’s the one people will actually reach for: that a pill for aging already exists, sitting in pharmacies under a blood-pressure label. It doesn’t. Nothing here has been shown to work in a human body. A study in worms and mice is a study in worms and mice, and there are no guarantees the drug does anything comparable in people.
What Nobody Knows Yet
Whether any of this does anything for a person taking rilmenidine for their blood pressure is genuinely unconfirmed; no trial has tested the drug for this purpose in people. It’s worth separating out a different, unrelated data point so it doesn’t get folded into the worm result: a long-term analysis followed 438 postmenopausal women, half prescribed metformin for diabetes and half prescribed a sulfonylurea drug, for an average of 14 to 15 years, and found the metformin group had a 30 percent lower calculated risk of dying before age 90. That’s an observational comparison of two existing diabetes drugs, not a controlled trial, and it says nothing about rilmenidine at all. The worm and mouse findings are specific and real. Whether caloric-restriction mimics are even the right target for human aging, given how mixed and hard to sustain actual restriction trials have been in people, is still an open question. The leap from a worm’s cells to a human pillbox has not been made, not by this study and not by anyone yet.